Sorafenib Benefit Unaffected by Prior Cytokine Therapy
Sorafenib treatment doubles progression-free survival in patients with advanced renal cell carcinoma, regardless of whether they have received prior cytokine therapy.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.